Intestinal transit of an orally administered streptomycin-rifampicin-resistant variant of Bifidobacterium longum SBT2928: its long-term survival and effect on the intestinal microflora and metabolism

Clicks: 450
ID: 117854
2001
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
It is clarified that BL2928SR has the ability for long-term survival in the human gastrointestinal tract, and alters the composition and metabolism of the intestinal microflora.
Reference Key
s2001journalintestinal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Fujiwara S;Seto Y;Kimura A;Hashiba H;;
Journal Journal of applied microbiology
Year 2001
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/11155121
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male Surveys and Questionnaires Bacteria / genetics Bacteria / isolation & purification* Feces / microbiology* drug resistance bifidobacterium / genetics intestines / microbiology* microbial* actinomycetales infections / microbiology bifidobacterium / physiology* hydrogen-ion concentration bacteria / growth & development bifidobacterium / growth & development multiple* mutation / genetics cell division intestinal mucosa / metabolism feces / chemistry pmid:11155121 doi:10.1046/j.1365-2672.2001.01205.x s fujiwara y seto h hashiba actinomycetales infections / enzymology actinomycetales infections / metabolism oral* ammonia / analysis feces / enzymology genetic variation / genetics intestines / chemistry intestines / enzymology probiotics / administration & dosage probiotics / metabolism random amplified polymorphic dna technique

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.